Pharvaris (NASDAQ:PHVS) Sets New 52-Week High – What’s Next?

Pharvaris N.V. (NASDAQ:PHVS) hit a new 52-week high on Wednesday . The stock traded as high as $36.10 and last traded at $35.75, with a volume of 526211 shares traded. The stock had previously closed at $34.59.

Analysts Set New Price Targets

Several equities analysts recently commented on PHVS shares. Morgan Stanley boosted their price target on Pharvaris from $41.00 to $46.00 and gave the stock an “overweight” rating in a research report on Thursday, June 25th. Wedbush lifted their price target on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 7th. Royal Bank Of Canada dropped their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Wall Street Zen raised Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Finally, HC Wainwright restated a “buy” rating on shares of Pharvaris in a research note on Tuesday, June 16th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $49.64.

Pharvaris Stock Performance

The company’s fifty day simple moving average is $31.31 and its two-hundred day simple moving average is $28.49. The company has a market capitalization of $2.34 billion, a price-to-earnings ratio of -11.24 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. Sell-side analysts anticipate that Pharvaris N.V. will post -3.2 EPS for the current year.

Insider Activity at Pharvaris

In other news, insider Anne Lesage sold 30,703 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,649.47. Following the completion of the sale, the insider directly owned 93,969 shares in the company, valued at approximately $3,334,959.81. The trade was a 24.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Berndt Modig sold 23,333 shares of the company’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $27.74, for a total value of $647,257.42. Following the sale, the chief executive officer directly owned 142,084 shares in the company, valued at approximately $3,941,410.16. This represents a 14.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 328,981 shares of company stock worth $10,458,873 over the last quarter.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. CoreCap Advisors LLC acquired a new position in Pharvaris during the 2nd quarter valued at approximately $93,000. Seven Fleet Capital Management LP increased its position in Pharvaris by 472.3% in the first quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock worth $8,947,000 after buying an additional 261,355 shares during the period. DV Trading LLC bought a new stake in Pharvaris in the first quarter valued at $4,067,000. Stempoint Capital LP boosted its holdings in shares of Pharvaris by 48.4% during the first quarter. Stempoint Capital LP now owns 86,637 shares of the company’s stock valued at $2,447,000 after acquiring an additional 28,248 shares during the period. Finally, ADAR1 Capital Management LLC boosted its holdings in shares of Pharvaris by 23.4% during the first quarter. ADAR1 Capital Management LLC now owns 105,528 shares of the company’s stock valued at $2,981,000 after acquiring an additional 20,000 shares during the period.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.